Drug Research
nVentic report reveals fast-growing manufacturer inventories fail to prevent medicine shortages
nVentic, the inventory optimization specialist, has today launched its 2023 Big Pharma Inventory Benchmarking Report. The report, which analyses the published corporate reports of 28 major pharmaceutical manufacturers, including Merck, AstraZeneca and Pfizer, is an annual look at the...
Drug Research
Advancement In Process Control With New PEACE Algorithm
Researchers have gone on to develop a physics-enhanced autocorrelation-based estimator (PEACE) machine learning algorithm that can go ahead with the extraction of the particle size distribution (PSD) of a pharmaceutical powder surface from its laser spot. The process provides...
Drug Research
High demand: Vetter expands production capacities and services offered at its Austrian site
Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), continues to drive the expansion of capacities and services for the provision of clinical trial materials: With the implementation of additional equipment for aseptic production and the expansion of...
Drug Research
Safe And Efficient Gene Editing With Virus-Derived Peptides
A novel approach within the genetic engineering of cells promises major enhancements when it comes to speed, effectiveness, and reduction in cellular toxicity as compared to the current methods. The approach could also go on to power advanced cell...
Drug Research
Complexity of APIs Drive OSD Contract Manufacturing Demand
For many years, the rising complexity of APIs has led to the development of a sea of novel formulations that help in the efficient delivery of drugs to the intended site where action needs to happen. Nevertheless, the demand...
Drug Research
European Medicines Agency recommends bimekizumab in two new indications
UCB, a global biopharmaceutical company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued positive opinions recommending granting marketing authorization for bimekizumab in the European Union (EU) for the...
Drug Research
FDA approves the manufacture of new microbiome-based therapeutic VOWSTTM at Recipharm site
Recipharm, a Global contract development and manufacturing organization (CDMO), has announced today that its subsidiary, GenIbet Biopharmaceuticals, has been approved by the US FDA as a manufacturing site of VOWST, a breakthrough orally administered fecal microbiota product for the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read